BioSpace News Archive

Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that management will participate in the following upcoming investor conferences: The Investor Summit Group’s Virtual Fall Summit, which is being held from November 16th - 18th. Management will present on Tuesday, November 17th at 1:00 p.m. Eastern Time. Alliance Global Partners’ Vir

Galafold 3Q20 Revenue of $67.4 Million, On-Track to Achieve Revenue Guidance of $250M-$260M AT-GAA Phase 3 PROPEL Study Readout in 1Q21 and Rolling BLA Submission to Begin in 4Q20 Positive CLN6 Batten Disease Gene Therapy Data Presented in October Fabry Disease Gene Therapy Clinical Candidate Selected Conference Call and Webcast Today at 8:30 a.m. ET

- Total revenues of $ 15.7 million and net product revenues of $ 5. 8 million - - S equential quarterly increase in underlying customer demand of over 12 0 % for DEXYCU ® and over 5% for YUTIQ® - - EYP-1901, a potential six-month sustained delivery intravitreal anti-VEGF treatment targeting wet age-related macular degeneration, remains on track for Q4 IND filing -

COMET Phase 3 long-term safety trial of AXS-05 in MDD, and MOVEMENT Phase 3 long-term safety trial of AXS-07 in migraine completed NDA submission s for AXS-05 in depression expected in January 2021, and for AXS-07 in migraine expected in 1Q 2021 Launch readiness activities progressing with buildout of Digital-Centric Commercialization (DCC™) platform Efficacy r esults from three Phase 2 open-label efficacy trials of AXS-05 in TRD, antidepressant unresponsive MDD,

RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that it will report its third-quarter 2020 financial results and business highlights on Thursday, November 12, 2020. The Company will host a conference call and webcast on Thursday , November 12 , 2020 , at 8:30 a.m. E S T , during which it will present key highlights for the third qu

Initial D ata from Phase 1 T rial of IGM-2323 in R elapsed/ r efractory N on-Hodgkin’s L ymphoma to be Presented at the 62nd American Society of Hematology Annual Meeting and Exposition in December - - First-in-Human Clinical Trial of IGM-8444 for the Treatment of Solid Cancers and Non-Hodgkin’s Lymphoma Initiated - IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology c

New data investigating IMBRUVICA® (ibrutinib) as time-limited therapy in chronic lymphocytic leukemia (CLL) and long-term results in CLL, mantle cell lymphoma (MCL) and Waldenström’s Macroglobulinemia (WM)

Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins , Chief Executive Officer and President, will virtually present a corporate overview at the Piper Sandler 32 nd Annual Healthcare Conference taking plac

- Initiated Phase 1/2 triple combination study to accelerate the direct evaluation of the DNAM axis hypothesis - Enrollment in COM701 Phase 1 monotherapy expansion cohort and Phase 1 COM902 dose escalation studies on track

Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company focused on the Phase 3 execution, registration and potential commercialization of momelotinib, a novel drug that may address serious unmet needs in myelofibrosis, today